Overview Dividends

(AMPH) Amphastar P - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032

Enoxaparin, Insulin, Glucagon, Naloxone, Epinephrine

AMPH EPS (Earnings per Share)

EPS Growth (3Y CAGR): -55.79%
EPS Trend (3Y Correlation): -29.6%

AMPH Revenue

Revenue Growth (3Y CAGR): 14.52%
Revenue Trend (3Y Correlation): 80.3%

Description: AMPH Amphastar P August 21, 2025

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a US-based company operating in the Pharmaceuticals sub-industry. The companys market capitalization stands at approximately $1.1 billion, indicating a mid-cap status. With a Return on Equity (ROE) of 19.37%, Amphastar demonstrates a relatively strong ability to generate profits from shareholder equity.

The stocks Price-to-Earnings (P/E) ratio is 8.92, suggesting that the company may be undervalued compared to its earnings. This could be an attractive feature for value investors. However, the forward P/E ratio is not available, potentially due to a lack of analyst estimates or significant variability in earnings forecasts.

Key drivers for Amphastars stock performance may include the companys product portfolio, pipeline developments, and competitive positioning within the pharmaceutical industry. Investors should monitor revenue growth, gross margin trends, and research and development (R&D) expenses to gauge the companys operational performance. Additionally, keeping track of regulatory updates and industry trends will be crucial in assessing Amphastars future prospects.

From a technical perspective, the stocks beta of 0.76 indicates relatively lower volatility compared to the broader market. This, combined with its current price near the 52-week high, suggests that Amphastars stock may be experiencing a degree of stability. Investors should continue to monitor moving averages, such as the SMA20 and SMA50, to identify potential trend reversals or continuations.

AMPH Stock Overview

Market Cap in USD	1,106m
Sub-Industry	Pharmaceuticals
IPO / Inception	2014-06-25

AMPH Stock Ratings

Growth Rating	-32.1%
Fundamental	73.1%
Dividend Rating	-
Return 12m vs S&P 500	-60.4%
Analyst Rating	3.67 of 5

AMPH Dividends

Currently no dividends paid

AMPH Growth Ratios

Growth Correlation 3m	-43.3%
Growth Correlation 12m	-70.7%
Growth Correlation 5y	51.7%
CAGR 5y	-7.28%
CAGR/Max DD 3y (Calmar Ratio)	-0.11
CAGR/Mean DD 3y (Pain Ratio)	-0.25
Sharpe Ratio 12m	-1.33
Alpha	-67.97
Beta	0.750
Volatility	37.96%
Current Volume	363.1k
Average Volume 20d	324.1k
Stop Loss	23.3 (-3.9%)
Signal	0.15

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (134.7m TTM) > 0 and > 6% of Revenue (6% = 43.2m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA -5.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 56.15% (prev 48.49%; Δ 7.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 159.7m > Net Income 134.7m (YES >=105%, WARN >=100%)

Net Debt (-139.9m) to EBITDA (248.1m) ratio: -0.56 <= 3.0 (WARN <= 3.5)

Current Ratio 3.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (48.1m) change vs 12m ago -7.53% (target <= -2.0% for YES)

Gross Margin 50.03% (prev 53.49%; Δ -3.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 46.37% (prev 47.80%; Δ -1.43pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.30 (EBITDA TTM 248.1m / Interest Expense TTM 25.7m) >= 6 (WARN >= 3)

Altman Z'' 4.47

(A) 0.25 = (Total Current Assets 580.8m - Total Current Liabilities 176.4m) / Total Assets 1.62b

(B) 0.39 = Retained Earnings (Balance) 625.1m / Total Assets 1.62b

(D) 0.72 = Book Value of Equity 619.7m / Total Liabilities 857.9m

Total Rating: 4.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 73.14

1. Piotroski 5.50pt = 0.50

2. FCF Yield 12.17% = 5.0

3. FCF Margin 15.58% = 3.89

4. Debt/Equity 0.06 = 2.50

5. Debt/Ebitda -0.56 = 2.50

6. ROIC - WACC (= 2.15)% = 2.69

7. RoE 18.15% = 1.51

8. Rev. Trend 80.35% = 6.03

9. EPS Trend -29.64% = -1.48

What is the price of AMPH shares?

As of October 30, 2025, the stock is trading at USD 24.24 with a total of 363,133 shares traded.
Over the past week, the price has changed by -1.14%, over one month by -9.96%, over three months by +11.86% and over the past year by -52.61%.

Is Amphastar P a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Amphastar P (NASDAQ:AMPH) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 73.14 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMPH is around 19.41 USD . This means that AMPH is currently overvalued and has a potential downside of -19.93%.

Is AMPH a buy, sell or hold?

Amphastar P has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold AMPH.

Strong Buy: 2
Buy: 0
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the AMPH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	32.5	34.1%
Analysts Target Price	32.5	34.1%
ValueRay Target Price	21.7	-10.4%

AMPH Fundamental Data Overview October 20, 2025

Market Cap USD = 1.11b (1.11b USD * 1.0 USD.USD)
P/E Trailing = 8.9064
P/S = 1.5299
P/B = 1.6278
P/EG = 2.77
Beta = 0.75
Revenue TTM = 720.3m USD
EBIT TTM = 187.5m USD
EBITDA TTM = 248.1m USD
Long Term Debt = 607.7m USD (from longTermDebt, last quarter)
Short Term Debt = 8.81m USD (from shortTermDebt, last quarter)
Debt = 47.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -139.9m USD (from netDebt column, last quarter)
Enterprise Value = 921.7m USD (1.11b + Debt 47.8m - CCE 231.8m)
Interest Coverage Ratio = 7.30 (Ebit TTM 187.5m / Interest Expense TTM 25.7m)
FCF Yield = 12.17% (FCF TTM 112.2m / Enterprise Value 921.7m)
FCF Margin = 15.58% (FCF TTM 112.2m / Revenue TTM 720.3m)
Net Margin = 18.70% (Net Income TTM 134.7m / Revenue TTM 720.3m)
Gross Margin = 50.03% ((Revenue TTM 720.3m - Cost of Revenue TTM 360.0m) / Revenue TTM)
Gross Margin QoQ = 49.59% (prev 49.99%)
Tobins Q-Ratio = 0.57 (Enterprise Value 921.7m / Total Assets 1.62b)
Interest Expense / Debt = 13.15% (Interest Expense 6.28m / Debt 47.8m)
Taxrate = 21.11% (8.30m / 39.3m)
NOPAT = 147.9m (EBIT 187.5m * (1 - 21.11%))
Current Ratio = 3.29 (Total Current Assets 580.8m / Total Current Liabilities 176.4m)
Debt / Equity = 0.06 (Debt 47.8m / totalStockholderEquity, last quarter 757.5m)
Debt / EBITDA = -0.56 (Net Debt -139.9m / EBITDA 248.1m)
Debt / FCF = -1.25 (Net Debt -139.9m / FCF TTM 112.2m)
Total Stockholder Equity = 742.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.34% (Net Income 134.7m / Total Assets 1.62b)
RoE = 18.15% (Net Income TTM 134.7m / Total Stockholder Equity 742.2m)
RoCE = 13.89% (EBIT 187.5m / Capital Employed (Equity 742.2m + L.T.Debt 607.7m))
RoIC = 11.00% (NOPAT 147.9m / Invested Capital 1.35b)
WACC = 8.85% (E(1.11b)/V(1.15b) * Re(8.78%) + D(47.8m)/V(1.15b) * Rd(13.15%) * (1-Tc(0.21)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.72%
[DCF Debug] Terminal Value 79.09% ; FCFE base≈138.6m ; Y1≈170.9m ; Y5≈291.6m
Fair Price DCF = 92.79 (DCF Value 4.31b / Shares Outstanding 46.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -29.64 | EPS CAGR: -55.79% | SUE: -4.0 | # QB: 0
Revenue Correlation: 80.35 | Revenue CAGR: 14.52% | SUE: 0.11 | # QB: 0

Additional Sources for AMPH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle